THAILANSTATINANALOGA

European patent · EP3684773 · In force

Register entry

Publication number
EP3684773
Application number
EP18789726
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Sep 19, 2018
Published
Jul 29, 2020
Granted
Apr 29, 2026
Protection ends at the latest
Sep 18, 2038
Next annual fee due
Sep 30, 2027
IPC classes
C07D 493/04 (2006.01)
A61P 35/00 (2006.01)
A61K 31/352 (2006.01)
Priority
US 201762561060 P 20.09.2017
US 201862686781 P 19.06.2018
PCT application
PCT/US2018/051721 19.09.2018
PCT publication
WO2019/060398 28.03.2019
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Oct 1, 2026

    Next annual fee due on

    Next annual fee due on
    30.09.2026 → 30.09.2027

    Published in Swissreg on 01.10.2026

  2. Apr 29, 2026

    Granted

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 29.04.2026

Parties

Holder

pH Pharma Co., Ltd.

9F, The-K Twin Towers A 50 Jongno 1-Gil Jongno-Gu, Seoul 03142, KR

Inventor

JAMMALAMADAKA, Vasu

Dublin, California 94568, US

TIPTON, Kimberly Ann

San Francisco, California 94122, US

SATYAL, Sanjeev

San Carlos, California 94070, US

HUH, Hoyoung

Portola Valley, California 94028, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.